Entera Bio (ENTXW) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for Entera Bio.

Research analysts covering Entera Bio.

Recent press releases and 8-K filings for ENTXW.

Entera Bio and OPKO Health Expand Partnership for Oral LA-PTH Tablet and Announce Board Change

ENTXW

New Projects/Investments

Board Change

Entera Bio Ltd. and OPKO Health, Inc. expanded their collaboration to advance a first-in-class oral long-acting PTH analog (LA-PTH) tablet for hypoparathyroidism, aiming to file an Investigational New Drug (IND) application in late 2026. For this new program, both companies will hold a 50% pro-rata ownership interest and share 50% of development costs.
Steve Rubin, Executive Vice President of Administration and director at OPKO, joined Entera's board of directors as a Class III director, effective February 1, 2026, replacing Gerry Ostrov. He was also appointed Chairman of the audit committee and a member of the compensation committee.
The previously announced 60%/40% (OPKO/Entera) ownership structure and cost-sharing arrangement for the oral oxyntomodulin (OXM) program for metabolic and fibrotic disorders remains unchanged.
OPKO Health is subject to a standstill period until March 16, 2027, regarding acquiring Entera Ordinary Shares or influencing management, and a lock-up period until March 16, 2026, preventing the sale of Entera Ordinary Shares.

2 days ago

Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates

ENTXW

Earnings

New Projects/Investments

Guidance Update

Entera Bio Ltd. reported a net loss of $3.2 million, or $0.07 per ordinary share, for the three months ended September 30, 2025.
As of September 30, 2025, the company held $16.6 million in cash and cash equivalents, including $8.0 million in restricted cash, with cash on hand expected to support operations through the middle of the third quarter of 2026.
The FDA agreed with Entera's proposal for a single multinational, randomized, double-blind, placebo-controlled, 24-month Phase 3 study for EB613, with change in total hip BMD as the primary endpoint.
The Next-Generation EB613 remains on track for Phase 1 initiation in late 2025, and an Investigational New Drug (IND) application for oral OXM is planned for H1 2026.